Health
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit
TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Unique sublingual formulation designed for bedtime dosing bypasses first-pass metabolism, optimizing parent-drug exposure during sleep and decreasing levels of the persistent active metabolite Treatment was well tolerated with minimal effects on weight or blood pressure CHATHAM, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or t
About this update from Tonix Pharmaceuticals Holding Corp.
[{"type":"image","alt":"Tonix Pharmaceuticals Holding Corp.","displaySize":"","headline":null,"caption":"Tonix Pharmaceuticals Holding Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":140,"url":"https://media.zenfs.com/en/globenewswire.com/7794549bf2784a219c2135212e93833d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bONNVXBcHa.udDsOM80N_g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7794549bf2784a219c2135212e93833d","width":300,"height":140}},"lazy":false},{"type":"text","content":"TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study","length":115,"tagName":"p"},{"type":"text","content":"Unique sublingual formulation designed for bedtime dosing bypasses first-pass metabolism, optimizing parent-drug exposure during sleep and decreasing levels of the persistent active metabolite","length":192,"tagName":"p"},{"type":"text","content":"Treatment was well tolerated with minimal effects on weight or blood pressure","length":77,"tagName":"p"},{"type":"text","content":"CHATHAM, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, presented data on TONMYA™, which was investigated as TNX-102 SL, at the 2026 Non-Opioid Pain Therapeutics Summit, on January 29, 2026, in Boston, Massachusetts. A copy of the Company's presentation, titled "TNX-102 SL (Sublingual Cyclobenzaprine HCl): a Centrally Acting Non-Opioid Analgesic for the Treatment of Fibromyalgia," is available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com.","length":640,"tagName":"p"},{"type":"text","content":""Fibromyalgia is a chronic pain disorder affecting more than 10 million adults in the U.S., with existing treatments often limited by tolerability and side effects," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "The data presented at the Non-Opioid Pain Therapeutics Summit by our Chief Medical Officer, Gregory Sullivan, M.D. highlight TONMYA'S role as a centrally-acting, differentiated non-opioid treatment. TONMYA'S unique sublingual formulation is designed for bedtime administration and to bypass firs...